/Investor DB

REDMILE — 2020 Investments

3 investments dated 2020 · listed companies and verified rows first · show all

Amunix Pharmaceuticalsamunix.comMar 2020 · $73M

Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.

BiotechSouth San Francisco, US

Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)

Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin Capital+6 more

Annexonannexonbio.comin𝕏Jul 2020 · $100M

Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.

BiotechHealthtechMedical DevicesSo. San Francisco, US

Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)

Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)BlackRockBlackstone Life SciencesClarus Ventures+2 more

LAVA Therapeuticslavatherapeutics.comin𝕏Sep 2020

LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.

AI & Machine LearningBiotechHealthtechMedical Devices

Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in

Co-investorsMRL Ventures FundSanofi VenturesYsios CapitalGilde HealthcareNovo Holdings

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.